Keppra Xr
Myoclonic Epilepsy, Juvenile, myoclonic seizures, Seizures + 4 more
Treatment
2 FDA approvals
4 Active Studies for Keppra Xr
Treatment for
Myoclonic Epilepsy, Juvenile
What is Keppra Xr
Levetiracetam
The Generic name of this drug
Treatment Summary
Levetiracetam is a medication used to treat various types of seizures caused by epileptic disorders. It was approved for use in the US in 1999 and is different from other anti-epileptic drugs. Levetiracetam has a wide therapeutic index and does not interact with other drugs, making it a desirable choice over other anti-epileptic drugs.
Keppra
is the brand name
Keppra Xr Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Keppra
Levetiracetam
2000
604
Approved as Treatment by the FDA
Levetiracetam, otherwise known as Keppra, is approved by the FDA for 2 uses like Partial-Onset Seizures and Seizures .
Partial-Onset Seizures
Seizures
Effectiveness
How Keppra Xr Affects Patients
Levetiracetam works to prevent seizures, although the exact way it does this is unknown. Its effectiveness is high compared to other anti-seizure medications. Taking levetiracetam can increase the risk of suicidal thoughts or behaviour, so patients should be monitored for signs of depression, suicidal thoughts, and changes in behaviour.
How Keppra Xr works in the body
Levetiracetam works in a unique way compared to other anti-epileptic drugs. It binds to a protein called synaptic vesicle protein 2A, which is found on cells in the brain and helps control how neurotransmitters are released. By binding to this protein, levetiracetam can reduce the amount of neurotransmitters released. This helps prevent the over-firing of neurons that can lead to seizures. Levetiracetam also has indirect effects on GABAergic and glutamatergic receptors, as well as ionic currents and calcium channels, although it's unclear yet how these effects contribute
When to interrupt dosage
The prescribed measure of Keppra Xr is contingent upon the recognized malady, for example Seizures, Juvenile myoclonic epilepsy and Epilepsies. The dosage also relies upon the methodology of delivery (e.g. Tablet, for suspension or Intravascular) provided in the table beneath.
Condition
Dosage
Administration
Disease
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
myoclonic seizures
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Seizures
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Epilepsy
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Epilepsy, Generalized
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Obesity
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Myoclonic Epilepsy, Juvenile
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Warnings
Keppra Xr Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Levetiracetam may interact with Pulse Frequency
There are 20 known major drug interactions with Keppra Xr.
Common Keppra Xr Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Levetiracetam is combined with Oliceridine.
Thalidomide
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Daridorexant
Minor
The risk or severity of CNS depression can be increased when Levetiracetam is combined with Daridorexant.
Keppra Xr Toxicity & Overdose Risk
The lowest toxic dose of levetiracetam in humans is 10 mg/kg. Symptoms of overdose may include restlessness, aggression, sleepiness, reduced consciousness, difficulty breathing, or a coma. There is no specific antidote for levetiracetam overdose, so treatment should focus on providing general support and managing symptoms. Hemodialysis can be used to reduce the amount of levetiracetam in the bloodstream by about 50% in 4 hours.
Keppra Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Keppra Xr?
Three active clinical trials are presently exploring the potential of Keppra Xr in ameliorating myoclonic seizures, Juvenile myoclonic epilepsy and Idiopathic Generalized Epilepsy.
Condition
Clinical Trials
Trial Phases
Epilepsy
0 Actively Recruiting
Seizures
5 Actively Recruiting
Phase 3, Phase 2, Phase 1
Epilepsy, Generalized
0 Actively Recruiting
myoclonic seizures
0 Actively Recruiting
Myoclonic Epilepsy, Juvenile
0 Actively Recruiting
Disease
0 Actively Recruiting
Obesity
0 Actively Recruiting
Keppra Xr Reviews: What are patients saying about Keppra Xr?
5
Patient Review
5/11/2013
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
5
Patient Review
9/14/2019
Keppra Xr for Simple Partial Seizures
5
Patient Review
2/3/2012
Keppra Xr for Convulsive Seizures
5
Patient Review
6/27/2014
Keppra Xr for Convulsive Seizures
5
Patient Review
12/8/2011
Keppra Xr for Convulsive Seizures
5
Patient Review
12/8/2011
Keppra Xr for Convulsive Seizures
5
Patient Review
2/3/2012
Keppra Xr for Convulsive Seizures
5
Patient Review
5/11/2013
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
5
Patient Review
6/27/2014
Keppra Xr for Convulsive Seizures
5
Patient Review
9/14/2019
Keppra Xr for Simple Partial Seizures
5
Patient Review
5/8/2014
Keppra Xr for Convulsive Seizures
5
Patient Review
5/8/2014
Keppra Xr for Convulsive Seizures
4.7
Patient Review
7/13/2015
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
4.7
Patient Review
7/13/2015
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
4.3
Patient Review
11/15/2013
Keppra Xr for Simple Partial Seizures
4.3
Patient Review
7/25/2016
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
4.3
Patient Review
11/15/2013
Keppra Xr for Simple Partial Seizures
4.3
Patient Review
7/25/2016
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
3.7
Patient Review
10/31/2012
Keppra Xr for Simple Partial Seizures
3.7
Patient Review
10/31/2012
Keppra Xr for Simple Partial Seizures
3
Patient Review
9/3/2013
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
3
Patient Review
5/22/2015
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
3
Patient Review
5/22/2015
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
3
Patient Review
9/3/2013
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
2.7
Patient Review
10/29/2014
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
2.7
Patient Review
10/29/2014
Keppra Xr for Additional Medication for Tonic-Clonic Epilepsy
2.3
Patient Review
6/14/2014
Keppra Xr for Simple Partial Seizures
2.3
Patient Review
6/14/2014
Keppra Xr for Simple Partial Seizures
1
Patient Review
1/24/2017
Keppra Xr for Simple Partial Seizures
1
Patient Review
1/24/2017
Keppra Xr for Simple Partial Seizures
Patient Q&A Section about keppra xr
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is Keppra XR used for?
"Keppra XR is an anti-seizure medication used to treat partial onset seizures in adults and children aged 4 and up, tonic-clonic seizures in adults and children aged 6 and up, and myoclonic seizures in adults and children."
Answered by AI
What is the difference between Keppra and Keppra XR?
"Keppra XR is the extended-release form of the same medication. The extended-release formulation allows the medicine to be released over a longer period of time. Most people require Keppra to be taken two or more times daily."
Answered by AI
How long does Keppra XR last?
"It takes about 44 hours for Keppra to be eliminated from your system."
Answered by AI
What are the side effects of Keppra XR?
"Side effects of Keppra XR may include infection, drowsiness, agitation, anxiety, depression, hostility, and irritability."
Answered by AI